Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a biopharmaceutical company focused on delivering innovative non-opioid pain therapies. The company operates through a portfolio of commercialized products and an advancing pipeline designed to address the significant medical need for alternatives to opioid-based pain… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pacira BioSciences, Inc. does
In the company’s own words
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a biopharmaceutical company focused on delivering innovative non-opioid pain therapies. The company operates through a portfolio of commercialized products and an advancing pipeline designed to address the significant medical need for alternatives to opioid-based pain management across multiple therapeutic areas.
The company's flagship product is EXPAREL, a long-acting local analgesic consisting of bupivacaine encapsulated in proprietary multivesicular liposome technology. EXPAREL is approved for postsurgical pain management via infiltration and regional anesthesia techniques including nerve blocks, and represents the company's largest revenue contributor at approximately 79 percent of total revenues. ZILRETTA, an extended-release intra-articular corticosteroid injection for osteoarthritis knee pain, accounts for approximately 16 percent of revenues. iovera° is a handheld cryoanalgesia device that delivers controlled cold temperature to targeted nerves for pain relief and represents a smaller but growing portion of the commercial portfolio.
Pacira's pipeline includes PCRX-201, a novel gene therapy candidate in Phase 2 development for osteoarthritis of the knee, which leverages the company's proprietary high-capacity adenovirus vector platform. The company's strategic growth plan, termed 5x30, targets delivery of products to over three million patients annually by 2030, double-digit revenue growth, improved gross margins, and expansion of its clinical pipeline and strategic partnerships.
The company was incorporated in Delaware in 2006 and has grown through strategic acquisitions including MyoScience in 2019, Flexion Therapeutics in 2021, and GQ Bio Therapeutics in 2025. EXPAREL generated net product sales of $575.1 million in 2025, while ZILRETTA contributed $116.6 million and iovera° contributed $24.2 million. The company maintains commercial operations across multiple surgical specialties including orthopedics, abdominal and colorectal surgery, women's health, cardiothoracic surgery, and pediatrics, with EXPAREL approved for use in patients as young as six years old. Pacira's website is www.pacira.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BRISBANE, CA
- Fiscal year end
- December
- CIK
- 1396814
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pacira BioSciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pacira BioSciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Pacira BioSciences, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Pacira BioSciences, Inc.’s debt, $13.40M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.13%, maturing 2029 to 2029.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pacira BioSciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pacira BioSciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pacira BioSciences, Inc.'s last four quarterly filings that the numbers alone won't show?”